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New-Onset Atrial Fibrillation Predicts
Long-Term Mortality After Coronary Artery Bypass Graft
Mikhael F. El-Chami, MD,* Patrick Kilgo, MS,§ Vinod Thourani, MD,† Omar M. Lattouf, MD,†
David B. Delurgio, MD,* Robert A. Guyton, MD,† Angel R. Leon, MD,*‡ John D. Puskas, MD†‡
Atlanta, Georgia
Objectives We sought to investigate the association between new-onset atrial fibrillation after coronary artery bypass
graft (CABG) (post-operative atrial fibrillation [POAF]) and long-term mortality in patients with no history of
atrial fibrillation.
Background POAF predicts longer hospital stay and greater post-operative mortality.
Methods A total of 16,169 consecutive patients with no history of AF who underwent isolated CABG at our institution be-
tween January 1, 1996, and December 31, 2007, were included in the study. All-cause mortality data were ob-
tained from Social Security Administration death records. A multivariable Cox proportional hazards regression
model was constructed to determine the independent impact of new-onset POAF on long-term survival after ad-
justing for several covariates. The covariates included age, sex, race, pre-operative risk factors (ejection fraction,
New York Heart Association functional class, history of myocardial infarction, index myocardial infarction, stroke,
chronic obstructive pulmonary disease, peripheral arterial disease, smoking, diabetes, renal failure, hyperten-
sion, dyslipidemia, creatinine level, dialysis, redo surgery, elective versus emergent CABG, any valvular disorder)
and post-operative adverse events (stroke, myocardial infarction, acute respiratory distress syndrome, and renal
failure), and discharge cardiac medications known to affect survival in patients with coronary disease.
Results New-onset AF occurred in 2,985 (18.5%) patients undergoing CABG. POAF independently predicted long-term
mortality (hazard ratio: 1.21; 95% confidence interval: 1.12 to 1.32) during a mean follow-up of 6 years (range 0
to 12.5 years). This association remained true after excluding from the analysis those patients who died in-
hospital after surgery (hazard ratio: 1.21; 95% confidence interval: 1.11 to 1.32). Patients with POAF discharged
on warfarin experienced reduced mortality during follow-up.
Conclusions In this large cohort of patients, POAF predicted long-term mortality. Warfarin anticoagulation may improve sur-
vival in POAF. (J Am Coll Cardiol 2010;55:1370–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.058(
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itrial fibrillation (AF) develops in 15% to 30% of patients
ndergoing isolated coronary artery bypass graft (CABG)
1–5). Post-CABG AF is associated with a longer hospital
tay and increased perioperative morbidity and early mor-
ality (6–8). Other studies have also suggested that post-
ABG AF affects long-term survival (5,9). The impact of
ew-onset AF after CABG has not been thoroughly ad-
ressed because many of these analyses did not exclude
atients with pre-existing paroxysmal AF (5,9). A history of
F predicts increased mortality in population-based studies
rom the Divisions of *Cardiology and †Cardiothoracic Surgery, Emory University
chool of Medicine; ‡Emory University Hospital Midtown; and the §Department of
iostatistics, Rollins School of Public Health, Emory University, Atlanta, Georgia.
r. Latouf is a consultant for Medtronic, Cardiogenesis, and Baxter.C
Manuscript received June 11, 2009; revised manuscript received October 19, 2009;
ccepted October 26, 2009.10), in patients with heart failure (11), and in patients with
nown coronary artery disease (12). Therefore, a history of
F before undergoing CABG may also be a risk factor for
ortality (13,14) after surgery. Whether new-onset AF
fter CABG, often considered a transient phenomenon
15), really predicts long-term mortality remains unan-
wered. We analyzed the effect of new-onset AF in patients
ndergoing CABG to determine whether it has an impact
n long-term mortality.
ethods
tudy protocol. We searched the Society of Thoracic
urgeons Adult Cardiac Database to identify consecutive
atients with no history of AF or flutter who underwent
solated CABG at Emory University Hospital or Emory
rawford Long Hospital between January 1, 1996, and
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March 30, 2010:1370–6 AF After CABG and Long-Term Mortalityecember 31, 2007. The study sample consists of 16,169
atients. Extracted records include demographic data,
re-existing comorbidities, and clinical outcomes. The
mory University Institutional Review Board approved
he protocol in compliance with Health Insurance Port-
bility and Accountability Act standards and the Decla-
ation of Helsinki. The Institutional Review Board
aived obtaining individual informed consent before
btaining the data on these patients.
We identified the primary study variable as the new onset of
F after CABG (post-operative atrial fibrillation [POAF]).
herefore, we excluded any patient with a pre-operative history
f paroxysmal or persistent AF. Pre-operative history of AF is
variable entered into the Society of Thoracic Surgeons (STS)
atabase and obtained by chart review and patient interview.
he study defines POAF according to the established STS
efinition, which defines new-onset AF as the occurrence of
OAF or atrial flutter requiring treatment (i.e., beta-blockers,
alcium-channel blockers, amiodarone, anticoagulation, or
ardioversion).
The primary end point, the survival time after surgery,
sed the date of death of patients in the cohort, as identified
y the Social Security Death Index (SSDI), a publicly
vailable national database of death records extracted from
he U.S. Social Security Administration’s Death Master File
xtract. The SSDI provided the date of death for each
atient who died before the cutoff date of June 30, 2008,
llowing computation of the Kaplan-Meier product-limit
stimates and associated Cox regressions. Because the SSDI
oes not describe the cause of death, the analysis describes
ll-cause long-term mortality.
To better ascertain the isolated effect of POAF on
ong-term survival, 32 covariates of long-term mortality risk
ere identified and harvested from the STS database for use
n a risk-adjustment analysis, using standard STS defini-
ions for each risk factor and outcome. The covariates
nalyzed included age, sex, race, left ventricular ejection
raction, history of myocardial infarction, index myocardial
nfarction, congestive heart failure (CHF), New York Heart
ssociation functional class, stroke, hypertension, diabetes
ellitus, renal failure, dyslipidemia, smoking, chronic ob-
tructive lung disease, peripheral vascular disease, the pres-
nce of left main disease (50%), last creatinine level,
ialysis status, elective versus nonelective CABG, redo
urgery, and the presence of any valvular disorder or
ost-operative complications (myocardial infarction, stroke,
ntra-aortic balloon pump, and post-operative respiratory
istress syndrome). We also analyzed the effect of any
ischarge medications known to influence survival in pa-
ients with coronary artery disease. These included
ngiotensin-converting enzyme inhibitors, beta-blockers,
ipid-lowering agents, amiodarone, aspirin, clopidogrel, and
arfarin.
We also examined the use and impact of warfarinnticoagulation after discharge on survival. aanagement of patients with
OAF. It is our practice to re-
tore sinus rhythm in the major-
ty of patients within 24 to 48
ours after the onset of POAF
ith the use of antiarrhythmic
rugs (AADs) or by electrical
ardioversion. Patients who are
ischarged home in AF are
aintained on warfarin (in the
bsence of any contraindication)
nd referred for cardioversion in
to 6 weeks. Patients discharged
ome on AADs are followed up
n the cardiology clinic in 3
onths. In the absence of evi-
ence of AF recurrence, their
ADs are stopped. The decision
o stop warfarin in this case is left to the cardiologist’s
iscretion. Thirty-day event recorder is performed on these
atients after stopping their AADs and on any symptoms
uggestive of AF recurrence. Initiation of warfarin therapy
n a patient with POAF is a decision left to the cardiologist
nd the cardiovascular surgery team caring for the patient.
tatistical analysis. Trained personnel devoted exclusively
o the task created and maintained a medical records
atabase. Data were 100% complete for POAF and survival
ime. Data were missing for the following pre-operative
haracteristics: ejection fraction (n  2,120, 13.1%); race
n  348, 2.2%); and last creatinine level (n  3,971,
4.6%). Multiple checks for data quality were performed
oth at the institutional level and before final entry into the
TS national adult cardiac database.
A multiple imputation algorithm was used to impute
issing values so that the whole sample could be analyzed to
void selection bias that can occur by deleting cases with
issing covariates. Ten datasets were imputed and estimates
rom these datasets were combined using methods described
y Molenberghs et al. (16). Values that were missing were
ssumed to be missing at random.
To statistically evaluate the isolated effect of POAF on
ortality, a multivariate Cox proportional hazards regres-
ion model was constructed that related survival time as a
unction of POAF, adjusting for the 32 covariates. Adjusted
azard ratios (HRs), along with 95% confidence intervals
CIs), were computed for POAF and the 32 covariates. The
roportional hazards assumption was verified by a correla-
ion analysis between the Schoenfeld residuals and ranked
ollow-up time.
Additionally, Kaplan-Meier product-limit estimates were
enerated to provide survival estimates at post-operative
oints in time. The Kaplan-Meier estimates for POAF
tatus were compared for equality using log-rank tests.
Data were managed and analyzed using SAS Version 9.2
SAS Institute Cary, North Carolina). The chi-square tests
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
CABG  coronary artery
bypass graft
CHF  congestive heart
failure
CI  confidence interval
HR  hazard ratio
POAF  post-operative
atrial fibrillation
SSDI  Social Security
Death Index
STS  Society of Thoracic
Surgeonsnd 2-sample t tests for categorical and continuous predic-
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AF After CABG and Long-Term Mortality March 30, 2010:1370–6ors, respectively, performed unadjusted comparisons. All
tatistical tests were 2 sided using an   0.05 level of
ignificance. No adjustments for multiple tests were made.
esults
ohort characteristics. Table 1 summarizes the character-
stics of the study population. The group consists of a
ajority of white men, mean age 61.7 years, of whom 75%
ad hypertension, 35% had diabetes, and 15% had a
iagnosis of CHF. The CABG procedure was performed
ithout cardiopulmonary bypass in 41.5% of patients.
POAF occurred in 2,985 (18.5%) patients. Tables 2 and 3
ummarize the characteristics of the cohort based on the
resence or absence of POAF. Patients with POAF were
lder and more likely to have known pre-operative risk
actors for AF or increased mortality (Table 2). They were
ohort CharacteristicsTable 1 Cohort Characteristics
n 16,196
Mean age, yrs (SD) 61.7 (10)
White 13,352 (82.6)
Male 11,638 (72.0)
Mean ejection fraction, % (SD) 50 (12.5)
Congestive heart failure 2,505 (15.5)
Diabetes 5,709 (35.3)
Hypertension 12,148 (75.1)
alues are n (%) unless otherwise indicated.
emographic and Pre-Operative Riskact rs by Presence of At ial Fibr llationTable 2 Demog aphic nd Pre-Operative RiskFactors by Presence of Atrial Fibrillation
Parameters
No POAF
(n  13,184)
POAF
(n  2,985) p Value
Age, yrs (SD) 61.3 (10.9) 67.5 (9.5) 0.001
Ejection fraction, % (SD) 50.6 (12.5) 49.9 (12.9) 0.008
Male 9,459 (71.7) 2,179 (73) 0.17
White 10,718 (81.3) 2,634 (88.2) 0.001
Myocardial infarction 6,513 (49.4) 1,545 (51.8) 0.02
Congestive heart failure 1,931 (14.7) 574 (19.2) 0.001
Chronic obstructive
pulmonary disease
1,814 (13.8) 495 (16.6) 0.001
Peripheral vascular disease 1,047 (7.9) 346 (11.6) 0.001
Left main coronary artery
disease
2,834 (21.5) 757 (25.4) 0.001
Smoking 3,595 (27.3) 600 (20.1) 0.001
Hypertension 9,781 (74.2) 2,367 (79.3) 0.001
Diabetes 4,648 (35.3) 1,061 (35.5) 0.77
Stroke 998 (7.6) 291 (9.8) 0.001
Creatinine level, mg/dl (SD) 1.2 (1.04) 1.32 (1.1.9) 0.001
Dialysis 186 (1.4) 66 (2.2) 0.001
Renal failure 765 (5.8) 243 (8.1) 0.001
Nonelective coronary artery
bypass graft
2,547 (19.3) 637 (21.3) 0.012
Dyslipidemia 4,514 (34.2) 1,055 (35.3) 0.25
Previous surgery 741 (5.6) 166 (5.6) 0.9
Any valvular disease 3,084 (23.4) 977 (32.7) 0.001alues are n (%) unless otherwise indicated.
POAF  post-operative atrial fibrillation.
Vlso more likely to have post-operative complications, in-
luding stroke, renal failure, and respiratory failure, and
ore likely to require an intra-aortic balloon pump for
emodynamic support (Table 3). The patients with POAF
ad a longer hospital stays than patients in whom AF did
ot develop (9.1 days vs. 5.4 days, p  0.001).
Assessment of the medications upon discharge shows that
atients with POAF were less likely to be discharged and
eceiving a beta-blocker, statin, or antiplatelet agent and
ere more likely to be discharged and receiving amiodarone
nd warfarin (Table 4). Only 20.5% of patients with AF
ere discharged and receiving warfarin.
urvival analysis. POAF was associated with an increased
isk of mortality over a mean follow-up period of 6 years
range 0 to 12 years). The unadjusted HR estimate for the
ffect of POAF on mortality measured 1.85 (95% CI: 1.71
o 1.99; p  0.001). As shown previously, patients with
OAF are a sicker cohort with more comorbid conditions
nd post-operative complications. The adjusted HR for
OAF was still statistically significant after adjusting for the
ffect of 32 different covariates (HR: 1.21, 95% CI: 1.12 to
.32; p 0.001). The Kaplan-Meier survival curves (Fig. 1)
iverge early and are increasingly separate over time. Of the
atients without POAF, 96.3% were alive 1 year after
urgery compared with 90.1% of patients with POAF. The
ifference in survival persisted at 10 years after surgery
70.2% vs. 55.2%, respectively). The survival difference
ost-Operative Risk Factorsy Pres nce of Atrial FibrillationTable 3 Post-Operative R sk Factorsby Presence of Atrial Fibrillation
Parameters
No POAF
(n  13,184)
POAF
(n  2,985) p Value
Post-operative myocardial
infarction
121 (0.9) 37 (1.2) 0.11
Post-operative stroke 174 (1.3) 94 (3.2) 0.001
Post-operative intra-aortic
balloon pump
22 (0.2) 12 (0.4) 0.011
Post-operative acute
respiratory distress
syndrome
50 (0.4) 37 (1.2) 0.001
Post-operative renal failure 57 (0.4) 64 (2.1) 0.001
alues are n (%).
Abbreviation as in Table 2.
ischarge Medications byresence of Atrial FibrillationTable 4 Dis harge Medications byPresence of Atrial Fibrillation
Parameters
No POAF
(n  13,184)
POAF
(n  2,985) p Value
Beta-blockers 11,880 (90.1) 2,332 (78.1) 0.001
Angiotensin-converting enzyme
inhibitor
4,220 (32.0) 935 (31.3) 0.47
Statins 5,575 (42.3) 1,197 (40.1) 0.029
Amiodarone 78 (0.6) 189 (16.4) 0.001
Aspirin 12,232 (92.8) 2,560 (85.8) 0.001
Warfarin 545 (4.1) 613 (20.5) 0.001
Clopidogrel 3,166 (24.0) 587 (19.7) 0.001alues are n (%).
Abbreviation as in Table 2.
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March 30, 2010:1370–6 AF After CABG and Long-Term Mortalityppears early and increases with time (6% at 1 year and
5% at 10 years). The initial analysis includes all patients
ho died during the initial hospitalization. To further
lucidate the role of POAF on long-term survival and to
xclude the confounding effect of in-hospital mortality
ossibly associated with POAF, the patients who died
efore discharge were deleted from a secondary analysis.
he negative impact of POAF on survival remained
nchanged in this selected sample of patients who sur-
ived the initial hospitalization (HR: 1.21, 95% CI: 1.11
o 1.32; p  0.001). As mentioned previously, 20.5% of
atients in whom POAF developed were discharged and
eceiving warfarin anticoagulation. Adjusting for the
ame 32 covariates, the adjusted effect of warfarin on
ortality in POAF patients seems to be protective (HR:
.78, 95% CI: 0.66 to 0.92). Therefore, patients with
OAF discharged and receiving warfarin experienced a
2% relative reduction in mortality compared with POAF
atients not receiving warfarin at discharge. Patients with
OAF receiving warfarin on discharge were more likely
o have an ejection fraction 30%, CHF, peripheral
ascular disease, hypertension, dyslipidemia, and diabetes
Table 5). The analysis did not address continual use of
arfarin during the follow-up period.
iscussion
his retrospective evaluation of more than 16,000 consec-
Figure 1 Kaplan-Meier Survival Curve
Continuous divergence in survival over time between patients with post-operative a
those with no post-operative atrial fibrillation. The numbers represent patients at rtrial fibrillation and
isk over time. AFIB  atrial fibrillation.tive patients undergoing CABG finds an association be-
Vemographic and Pre-Operative Riskact rs for POAF atients by Warfarin UseTable 5 Demog aphic nd Pre-Operative RiskFactors for POAF Patients by Warfarin Use
Parameters
No Warfarin
(n  2,372)
Warfarin
(n  613) p Value
Age, yrs (SD) 67.5 (9.6) 67.8 (9.0) 0.44
Ejection fraction, % (SD) 50.3 (12.7) 48.2 (13.6) 0.001
% of patients with ejection
fraction 30%
21 25 0.04
Male 1,711 (72.1) 468 (76.4) 0.036
White 2,039 (88.0) 533 (88.0) 0.97
Myocardial infarction 1,209 (51.0) 336 (54.8) 0.09
Congestive heart failure 435 (18.3) 139 (22.7) 0.015
Chronic obstructive
pulmonary disease
385 (16.2) 110 (17.9) 0.31
Peripheral vascular disease 250 (10.5) 96 (15.7) 0.001
Left main coronary artery
disease
606 (25.6) 151 (24.6) 0.64
Smoking 478 (20.2) 122 (19.9) 0.89
Hypertension 1,848 (77.9) 519 (84.7) 0.001
Diabetes 819 (34.5) 242 (39.5) 0.023
Stroke 221 (9.3) 70 (11.4) 0.12
Creatinine level, mg/dl (SD) 1.32 (1.20) 1.30 (1.17) 0.75
Dialysis 51 (2.2) 15 (2.5) 0.66
Renal failure 187 (7.9) 56 (9.1) 0.31
Nonelective coronary artery
bypass graft
507 (21.3) 130 (21.2) 0.93
Dyslipidemia 808 (34.1) 247 (40.3) 0.004
Previous surgery 132 (5.6) 34 (5.6) 0.99alues are n (%) unless otherwise indicated.
Abbreviation as in Table 2.
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AF After CABG and Long-Term Mortality March 30, 2010:1370–6ween POAF and a 21% relative increase in mortality. This
ncrease was true after controlling for multiple demographic
ariables, pre-operative risk factors, post-operative compli-
ations, and use of discharge medications. Of note, the
urvival difference emerged early and increased over time,
ith a 10-year survival rate of 55% in the POAF group
ompared with 70% in the no-AF group. In addition, this
urvival difference was seen in different identified subgroups
a trend was observed in nonwhite patients and in patients
ndergoing off-pump coronary bypass) (Table 6). In particular,
OAF had the greatest negative impact on long-term survival
n women (HR: 1.46, 5% CI: 1.27 to 1.67) (Table 6).
In patients in whom POAF developed, warfarin use at
ischarge was associated with a lower long-term mortality.
he use of warfarin was not controlled, and the difference in
ortality in patients with POAF was purely observational.
owever, the group receiving warfarin seems to be a
omewhat sicker population with higher demographic and
re-operative risk factors. The lower long-term mortality in
he POAF group receiving warfarin suggests a protective
ffect, perhaps from prevention of thromboembolism and
troke. The continuing divergence of the POAF and no-
OAF survival curves over time should prompt reconsider-
tion of the label given to new-onset POAF as a benign,
ransient phenomenon. Also, the observed association be-
ween use of warfarin at discharge in patients with POAF
nd reduced long-term mortality should prompt further
tudy of the use of warfarin in POAF, perhaps in a
andomized, controlled fashion.
omparison with previous studies. Our report is not the
rst analysis of POAF in patients undergoing CABG.
ariscalco et al. (9) addressed new-onset POAF in a study
f CABG at 2 Italian centers. They reported findings in
,832 patients undergoing isolated CABG; POAF occurred
n 31% of patients and was associated with increased short-
nd long-term mortality. However, those investigators did
ot exclude patients with a history of paroxysmal AF from
he analysis of POAF after CABG. Because a history of AF
s associated with increased mortality in population studies
nd in patients with coronary artery disease, their reported
ssociation between POAF and mortality could have been
iased by the effect of pre-existing AF on long-term
ortality in patients with coronary artery disease requiring
trial Fibrillation as a Predictor ofortality Among Different Subgr upsTable 6 Atrial Fibrilla ion as a Predictor ofMortality Among Different Subgroups
Group
Adjusted POAF Hazard Ratio
(95% CI) p Value
All patients 1.21 (1.12–1.32) 0.001
Females 1.46 (1.27–1.67) 0.001
Male 1.13 (1.02–1.24) 0.019
White 1.23 (1.12–1.34) 0.001
Nonwhite 1.18 (0.93–1.48) 0.17
Off-pump 1.12 (0.96–1.31) 0.14
On-pump 1.24 (1.13–1.36) 0.001abbreviation as in Table 2.ABG. The study also lost 8% of patients to follow-up and
herefore potentially lacked mortality data on those individ-
als. Use of the SSDI made mortality data available for all
he patients included in our study. Interestingly, the Italian
tudy determined the cause-specific mortality in POAF and
dentified the main cause of death in patients with POAF as
mbolic events. Paradoxically, warfarin therapy was associated
ith higher long-term mortality. The authors acknowledged
hat warfarin was prescribed in a sicker cohort of patients. One
ust note that the total number of patients with POAF
ischarged on warfarin was relatively small (n 90) compared
ith our study, which included more than 600 patients with
OAF discharged and receiving warfarin.
Villareal et al. (5) reported an association between POAF
nd late mortality in 6,475 patients undergoing first-time
evascularization surgery at the Texas Heart Institute.
OAF occurred in 16% patients. Those patients with POAF
ppeared to be older and sicker than those without POAF, a
nding consistently seen in other studies (17–20) and in
urs. Although the investigators adjusted for many comor-
id conditions when testing the effect of POAF on mortal-
ty, they did not account for the effect of race (21,22),
jection fraction (23), the presence of concomitant valve
isease (15), dialysis (24), left main coronary artery disease
25), or creatinine level (26,27). The Texas Heart Institute
tudy did not find an association between warfarin use on
ischarge and reduced mortality in POAF. The relatively
mall number of patients studied and discharged receiving
arfarin may have prevented meaningful analysis.
tudy implications. The possible impact of POAF on long-
erm mortality undermines the notion that newly diagnosed,
eemingly transient, post-CABG AF represents a benign event
n these patients. Furthermore, the association between war-
arin use and decreased long-term mortality in POAF patients
uggests that a protective effect against thromboembolic stroke,
he major cause of death attributable to AF, may have been
esponsible for the benefit. We detected a greater association
etween POAF and mortality in women (HR: 1.46, 95% CI:
.27 to 1.67 vs. the general population estimated HR of 1.21),
onsistent with the observation that women with AF have a
igher risk of stroke compared with men (28).
The notion that POAF can be attributed to post-operative
nflammation and oxidative stress (29–31) may suggest that it
s a transient phenomenon and may explain the low use of
arfarin in patients with POAF. The rates of warfarin use
eported in this setting in Europe (16%) (9) and the U.S. (14%)
5) were slightly below that of our cohort. Patients receiving
arfarin on discharge in our population exhibited greatest risk
f stroke based on the presence of diabetes, hypertension, or
HF (Table 5), suggesting recognition of a greater need for
nticoagulation at the time of discharge.
These results support other recent observations that
OAF should not be considered a transient phenomenon
nd may herald a continuing risk of recurrent AF with all
ts manifestations and complications, particularly stroke
nd death. The limited data on the effect of warfarin use
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March 30, 2010:1370–6 AF After CABG and Long-Term Mortalityn our population suggest the need for controlled, ran-
omized analysis of warfarin use in newly diagnosed
OAF. Our observations suggest that in the absence of
ata from controlled trials, one should consider the need
or warfarin therapy in patients with newly diagnosed
ost-CABG AF and known risk factors for stroke (CHF,
ypertension, age older than 75 years, diabetes, or pre-
ious stroke).
tudy limitations. This report involves a retrospective
nd observational analysis of single-center data on post-
ABG. Our regression model contains 32 covariates that
ose a potential for model overfitting and other associ-
ted estimation problems. The STS database was not
esigned to assess the effect of POAF on long-term
ortality, so some unknown variables that confound this
ssociation may not have been analyzed. Furthermore,
he STS database defines AF as requiring specific therapy
uch as medication or direct current cardioversion.
learly, shorter episodes of AF for which therapy is not
dministered would not have been classified and would
ave been excluded from the analysis. Whether AF not
equiring therapy affects long-term mortality cannot be
nswered by this analysis. Use of warfarin for POAF was not
ontrolled or randomized. Physician discretion, based on indi-
idual patient characteristics, led to its prescription. We also
annot determine the duration of warfarin therapy or its
ffectiveness based on therapeutic international normalized
atio targets, nor do we have specific data on bleeding and
troke occurrence during follow-up. However, our observations
o suggest that in a large cohort of patients without previous
F, the new onset of AF after CABG is associated with
ncreased long-term mortality.
onclusions
n this large cohort of patients undergoing isolated CABG,
OAF is associated with greater long-term mortality. War-
arin use in patients with POAF was associated with 22%
elative risk reduction of adjusted mortality. These findings
mplicate embolic events as a potential cause of death in
atients with newly diagnosed POAF. Anticoagulation
hould be considered for patients with POAF and known
isk factors for stroke.
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